Plasminogen intravenous - ProMetic Life Sciences

Drug Profile

Plasminogen intravenous - ProMetic Life Sciences

Latest Information Update: 19 May 2017

Price : $50

At a glance

  • Originator ProMetic Life Sciences
  • Class Antithrombotics; Beta-globulins
  • Mechanism of Action Plasmin modulators; Plasminogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type I plasminogen deficiency
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Type I plasminogen deficiency
  • Preclinical Wounds

Most Recent Events

  • 10 May 2017 Prometic Life Sciences plans to file for regulatory approval in Canada
  • 10 May 2017 Prometic Life Sciences plan a phase II trial for Wounds
  • 05 Apr 2017 ProMetic Biosciences completes the filing of BLA for Plasminogen intravenous for Type-I Plasminogen deficiency in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top